PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TAK vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


TAKLLY
YTD Return-4.74%32.74%
1Y Return-14.79%77.58%
3Y Return (Ann)-4.12%59.85%
5Y Return (Ann)-0.98%48.29%
10Y Return (Ann)0.10%32.09%
Sharpe Ratio-0.912.59
Daily Std Dev17.19%30.03%
Max Drawdown-52.14%-68.27%
Current Drawdown-40.27%-2.50%

Fundamentals


TAKLLY
Market Cap$41.69B$722.31B
EPS$0.29$6.76
PE Ratio45.69112.43
PEG Ratio3.231.43
Revenue (TTM)$4.17T$35.93B
Gross Profit (TTM)$2.44T$21.91B
EBITDA (TTM)$1.21T$13.37B

Correlation

-0.50.00.51.00.1

The correlation between TAK and LLY is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

TAK vs. LLY - Performance Comparison

In the year-to-date period, TAK achieves a -4.74% return, which is significantly lower than LLY's 32.74% return. Over the past 10 years, TAK has underperformed LLY with an annualized return of 0.10%, while LLY has yielded a comparatively higher 32.09% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


0.00%500.00%1,000.00%1,500.00%2,000.00%2,500.00%December2024FebruaryMarchAprilMay
7.94%
2,459.10%
TAK
LLY

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Takeda Pharmaceutical Company Limited

Eli Lilly and Company

Risk-Adjusted Performance

TAK vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


TAK
Sharpe ratio
The chart of Sharpe ratio for TAK, currently valued at -0.91, compared to the broader market-2.00-1.000.001.002.003.004.00-0.91
Sortino ratio
The chart of Sortino ratio for TAK, currently valued at -1.16, compared to the broader market-4.00-2.000.002.004.006.00-1.16
Omega ratio
The chart of Omega ratio for TAK, currently valued at 0.86, compared to the broader market0.501.001.502.000.86
Calmar ratio
The chart of Calmar ratio for TAK, currently valued at -0.38, compared to the broader market0.002.004.006.00-0.38
Martin ratio
The chart of Martin ratio for TAK, currently valued at -1.55, compared to the broader market-10.000.0010.0020.0030.00-1.55
LLY
Sharpe ratio
The chart of Sharpe ratio for LLY, currently valued at 2.59, compared to the broader market-2.00-1.000.001.002.003.004.002.59
Sortino ratio
The chart of Sortino ratio for LLY, currently valued at 3.81, compared to the broader market-4.00-2.000.002.004.006.003.81
Omega ratio
The chart of Omega ratio for LLY, currently valued at 1.48, compared to the broader market0.501.001.502.001.48
Calmar ratio
The chart of Calmar ratio for LLY, currently valued at 6.30, compared to the broader market0.002.004.006.006.30
Martin ratio
The chart of Martin ratio for LLY, currently valued at 18.80, compared to the broader market-10.000.0010.0020.0030.0018.80

TAK vs. LLY - Sharpe Ratio Comparison

The current TAK Sharpe Ratio is -0.91, which is lower than the LLY Sharpe Ratio of 2.59. The chart below compares the 12-month rolling Sharpe Ratio of TAK and LLY.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00December2024FebruaryMarchAprilMay
-0.91
2.59
TAK
LLY

Dividends

TAK vs. LLY - Dividend Comparison

TAK's dividend yield for the trailing twelve months is around 4.66%, more than LLY's 0.63% yield.


TTM20232022202120202019201820172016201520142013
TAK
Takeda Pharmaceutical Company Limited
4.66%4.41%4.05%5.90%4.34%5.74%8.33%5.15%6.93%5.31%5.00%3.90%
LLY
Eli Lilly and Company
0.63%0.78%1.07%1.23%1.75%1.96%1.94%2.46%2.77%2.37%2.84%3.84%

Drawdowns

TAK vs. LLY - Drawdown Comparison

The maximum TAK drawdown since its inception was -52.14%, smaller than the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for TAK and LLY. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%December2024FebruaryMarchAprilMay
-40.27%
-2.50%
TAK
LLY

Volatility

TAK vs. LLY - Volatility Comparison

The current volatility for Takeda Pharmaceutical Company Limited (TAK) is 5.12%, while Eli Lilly and Company (LLY) has a volatility of 10.44%. This indicates that TAK experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%December2024FebruaryMarchAprilMay
5.12%
10.44%
TAK
LLY

Financials

TAK vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Takeda Pharmaceutical Company Limited and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items